Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand

Click to increase image sizeClick to decrease image size

Acknowledgments

We would like to thank the staff of the Center of Excellence in Clinical Virology and all the participants for helping and supporting this project. We also thank the Ministry of Public Health, Chulabhorn Royal Academy, and Zuellig Pharma for providing the vaccines for this study.

Disclosure statement

All authors have declared no competing interests.

Additional information

Funding

This work was supported by the National Research Council of Thailand, the Health Systems Research Institute, the Center of Excellence in Clinical Virology of Chulalongkorn University, King Chulalongkorn Memorial Hospital, MK Restaurant Group, and the Second Century Fund Fellowship of Chulalongkorn University.